Biology of Blood and Marrow Transplantation
Volume 14, Issue 4 , Pages 449-457 , April 2008

Impact of Graft Cell Dose on Transplant Outcomes following Unrelated Donor Allogeneic Peripheral Blood Stem Cell Transplantation: Higher CD34+ Cell Doses Are Associated with Decreased Relapse Rates

  • Ryotaro Nakamura

      Affiliations

    • Division of Hematology/Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California
    • Corresponding Author InformationCorrespondence and reprint requests: Ryotaro Nakamura, MD, Division of Hematology/Hematopoietic Cell Transplantation, City of Hope National Medical Center, 1500 East Duarte Road, Duarte, California 91010-3000.
    • ,
  • Nademanee Auayporn

      Affiliations

    • Division of Hematology/Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California
    • ,
  • David D. Smith

      Affiliations

    • Department of Biostatistics, City of Hope National Medical Center, Duarte, California
    • These authors contributed equally to this article.
    • ,
  • Joycelynne Palmer

      Affiliations

    • Department of Biostatistics, City of Hope National Medical Center, Duarte, California
    • These authors contributed equally to this article.
    • ,
  • Joel Y. Sun

      Affiliations

    • Division of Hematology/Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California
    • ,
  • Jeffrey Schriber

      Affiliations

    • City of Hope/Samaritan Hematopoietic Cell Transplantation Program, Phoenix, Arizona
    • ,
  • Vinod Pullarkat

      Affiliations

    • Division of Hematology/Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California
    • ,
  • Pablo Parker

      Affiliations

    • Division of Hematology/Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California
    • ,
  • Roberto Rodriguez

      Affiliations

    • Division of Hematology/Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California
    • ,
  • Anthony Stein

      Affiliations

    • Division of Hematology/Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California
    • ,
  • Joseph Rosenthal

      Affiliations

    • Division of Hematology/Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California
    • ,
  • Shirong Wang

      Affiliations

    • Department of Transfusion Medicine, City of Hope National Medical Center, Duarte, California
    • ,
  • Chatchada Karanas

      Affiliations

    • Division of Hematology/Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California
    • ,
  • Karl Gaal

      Affiliations

    • Department of Anatomic Pathology, City of Hope National Medical Center, Duarte, California
    • ,
  • David Senitzer

      Affiliations

    • Division of Hematology/Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California
    • ,
  • Stephen J. Forman

      Affiliations

    • Division of Hematology/Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California

Received 13 December 2007 ,Accepted 6 February 2008.

References 

  1. Mavroudis D, Read E, Cottler-Fox M, et al. CD34+ cell dose predicts survival, posttransplant morbidity, and rate of hematologic recovery after allogeneic marrow transplants for hematologic malignancies. Blood. 1996;88:3223–3229
  2. Nakamura R, Bahceci E, Read EJ, et al. Transplant dose of CD34(+) and CD3(+) cells predicts outcome in patients with haematological malignancies undergoing T cell-depleted peripheral blood stem cell transplants with delayed donor lymphocyte add-back. Br J Haematol. 2001;115:95–104
  3. Ringden O, Barrett AJ, Zhang MJ, et al. Decreased treatment failure in recipients of HLA-identical bone marrow or peripheral blood stem cell transplants with high CD34 cell doses. Br J Haematol. 2003;121:874–885
  4. Dominietto A, Lamparelli T, Raiola AM, et al. Transplant-related mortality and long-term graft function are significantly influenced by cell dose in patients undergoing allogeneic marrow transplantation. Blood. 2002;100:3930–3934
  5. Sierra J, Storer B, Hansen JA, et al. Transplantation of marrow cells from unrelated donors for treatment of high-risk acute leukemia: the effect of leukemic burden, donor HLA-matching, and marrow cell dose. Blood. 1997;89:4226–4235
  6. Bittencourt H, Rocha V, Chevret S, et al. Association of CD34 cell dose with hematopoietic recovery, infections, and other outcomes after HLA-identical sibling bone marrow transplantation. Blood. 2002;99:2726–2733
  7. Perez-Simon JA, Diez-Campelo M, Martino R, et al. Impact of CD34+ cell dose on the outcome of patients undergoing reduced-intensity-conditioning allogeneic peripheral blood stem cell transplantation. Blood. 2003;102:1108–1113
  8. Gorin NC, Labopin M, Boiron JM, et al. Results of genoidentical hemopoietic stem cell transplantation with reduced intensity conditioning for acute myelocytic leukemia: higher doses of stem cells infused benefit patients receiving transplants in second remission or beyond—The Acute Leukemia Working Party of the European Cooperative Group for Blood and Marrow Transplantation. J Clin Oncol. 2006;24:3959–3966
  9. Przepiorka D, Smith TL, Folloder J, et al. Risk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantation. Blood. 1999;94:1465–1470
  10. Zaucha JM, Gooley T, Bensinger WI, et al. CD34 cell dose in granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell grafts affects engraftment kinetics and development of extensive chronic graft-versus-host disease after human leukocyte antigen-identical sibling transplantation. Blood. 2001;98:3221–3227
  11. Mohty M, Bilger K, Jourdan E, et al. Higher doses of CD34+ peripheral blood stem cells are associated with increased mortality from chronic graft-versus-host disease after allogeneic HLA-identical sibling transplantation. Leukemia. 2003;17:869–875
  12. Remberger M, Ringden O, Blau I-W, et al. No difference in graft-versus-host disease, relapse, and survival comparing peripheral stem cells to bone marrow using unrelated donors. Blood. 2001;98:1739–1745
  13. Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002;295:2097–2100
  14. Giebel S, Locatelli F, Lamparelli T, et al. Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood. 2003;102:814–819
  15. Davies SM, Ruggieri L, DeFor T, et al. Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants: killer immunoglobulin-like receptor. Blood. 2002;100:3825–3827
  16. Miller JS, Cooley S, Parham P, et al. Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT. Blood. 2007;109:5058–5061
  17. Savani BN, Rezvani K, Mielke S, et al. Factors associated with early molecular remission after T cell-depleted allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood. 2006;107:1688–1695
  18. Schaffer M, Olerup O. HLA-AB typing by polymerase-chain reaction with sequence-specific primers: more accurate, less errors, and increased resolution compared to serological typing. Tissue Antigens. 2001;58:299–307
  19. Sun JY, Gaidulis L, Miller MM, et al. Development of a multiplex PCR-SSP method for Killer-cell immunoglobulin-like receptor genotyping. Tissue Antigens. 2004;64:462–468
  20. Beelen DW, Ottinger H, Ferencik S, et al. Genotypic inhibitory killer immunoglobulin-like receptor ligand incompatibility enhances the long-term antileukemic effect of unmodified allogeneic hematopoietic stem cell transplantation in patients with myeloid leukemias. Blood. 2005;105:2594–2600
  21. Hsu KC, Keever-Taylor CA, Wilton A, et al. Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. Blood. 2005;105:4878–4884
  22. Blume KG, Forman SJ, Appelbaum FR. Thomas' Hematopoietic Cell Transplantation. 3rd ed.. Malden, MA: Blackwell Scientific Publications; 2004;
  23. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant. 1995;15:825–828
  24. Shulman HM. Graft-versus-host disease. Surv Synth Pathol Res. 1984;3:233–234
  25. Kaplan G, Meier P. Non-parametric estimations from incomplete observations. J Am Stat Assoc. 1958;53:457–481
  26. Peto R, Peto J. Asymptotically efficient rank invariant test procedures (with discussion). J R Stat Soc A. 1972;135:195–206
  27. Hauck WW, Donner A. Wald's test as applied to hypotheses in logit analysis. J Am Stat Assoc. 1977;72:851–853
  28. Cox DR. Regression models and life tables. J R Stat Soc B. 1972;34:187–220
  29. Jiang YZ, Barrett AJ, Goldman JM, Mavroudis DA. Association of natural killer cell immune recovery with a graft-versus-leukemia effect independent of graft-versus host disease following allogeneic bone marrow transplantation. Ann Hematol. 1997;74:1–6
  30. Niederwieser D, Gastl G, Rumpold H, Marth C, Kraft D, Huber C. Rapid reappearance of large granular lymphocytes (LGL) with concomitant reconstitution of natural killer (NK) activity after human bone marrow transplantation (BMT). Br J Haematol. 1987;65:301–305
  31. Boyington JC, Sun PD. A structural perspective on MHC class I recognition by killer cell immunoglobulin-like receptors. Mol Immunol. 2002;38:1007–1021
  32. Gumperz JE, Litwin V, Phillips JH, Lanier LL, Parham P. The Bw4 public epitope of HLA-B molecules confers reactivity with natural killer cell clones that express NKB1, a putative HLA receptor. J Exp Med. 1995;181:1133–1144
  33. Gumperz JE, Barber LD, Valiante NM, et al. Conserved and variable residues within the Bw4 motif of HLA-B make separable contributions to recognition by the NKB1 killer cell-inhibitory receptor. J Immunol. 1997;158:5237–5241
  34. Kim DH, Kim JG, Sohn SK, et al. Clinical impact of early absolute lymphocyte count after allogeneic stem cell transplantation. Br J Haematol. 2004;125:217–224

PII: S1083-8791(08)00070-0

doi: 10.1016/j.bbmt.2008.02.005

Biology of Blood and Marrow Transplantation
Volume 14, Issue 4 , Pages 449-457 , April 2008

Article Tools

* Image Usage & Resolution